DBV Technologies S.A. - Asset Resilience Ratio
DBV Technologies S.A. (DBV) has an Asset Resilience Ratio of 28.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how DBV Technologies S.A.'s Asset Resilience Ratio has changed over time. Check DBV Technologies S.A. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down DBV Technologies S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DBV Technologies S.A. (DBV) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €67.05 Million | 28.68% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €67.05 Million | 28.68% |
Asset Resilience Insights
- Very High Liquidity: DBV Technologies S.A. maintains exceptional liquid asset reserves at 28.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
DBV Technologies S.A. Industry Peers by Asset Resilience Ratio
Compare DBV Technologies S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for DBV Technologies S.A. (2007–2025)
The table below shows the annual Asset Resilience Ratio data for DBV Technologies S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.68% | €67.05 Million ≈ $78.39 Million |
€233.75 Million ≈ $273.27 Million |
-- |
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€65.66 Million ≈ $76.76 Million |
-- |
| 2023-12-31 | 64.18% | €117.44 Million ≈ $137.30 Million |
€182.99 Million ≈ $213.93 Million |
-8.47pp |
| 2022-12-31 | 72.65% | €179.09 Million ≈ $209.38 Million |
€246.50 Million ≈ $288.18 Million |
+41.39pp |
| 2021-12-31 | 31.27% | €45.87 Million ≈ $53.63 Million |
€146.72 Million ≈ $171.53 Million |
-14.86pp |
| 2020-12-31 | 46.13% | €154.01 Million ≈ $180.06 Million |
€333.87 Million ≈ $390.33 Million |
+2.02pp |
| 2019-12-31 | 44.11% | €135.37 Million ≈ $158.27 Million |
€306.90 Million ≈ $358.80 Million |
+0.46pp |
| 2018-12-31 | 43.65% | €102.47 Million ≈ $119.79 Million |
€234.76 Million ≈ $274.45 Million |
-50.59pp |
| 2017-12-31 | 94.23% | €235.86 Million ≈ $275.74 Million |
€250.28 Million ≈ $292.61 Million |
+57.60pp |
| 2016-12-31 | 36.64% | €116.20 Million ≈ $135.85 Million |
€317.16 Million ≈ $370.79 Million |
+36.23pp |
| 2013-12-31 | 0.41% | €345.41K ≈ $403.82K |
€84.80 Million ≈ $99.14 Million |
-0.31pp |
| 2009-12-31 | 0.72% | €49.00K ≈ $57.29K |
€6.79 Million ≈ $7.94 Million |
-0.51pp |
| 2008-12-31 | 1.23% | €49.00K ≈ $57.29K |
€3.98 Million ≈ $4.66 Million |
+0.61pp |
| 2007-12-31 | 0.63% | €49.00K ≈ $57.29K |
€7.84 Million ≈ $9.16 Million |
-- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more